Prime Capital Investment Advisors LLC purchased a new stake in Xylem Inc. (NYSE:XYL – Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 1,811 shares of the industrial products company’s stock, valued at approximately $207,000.
A number of other institutional investors and hedge funds have also recently bought and sold shares of XYL. Panagora Asset Management Inc. raised its holdings in shares of Xylem by 21.7% in the first quarter. Panagora Asset Management Inc. now owns 14,297 shares of the industrial products company’s stock valued at $1,219,000 after buying an additional 2,550 shares during the last quarter. Yousif Capital Management LLC raised its holdings in shares of Xylem by 1.5% in the first quarter. Yousif Capital Management LLC now owns 27,307 shares of the industrial products company’s stock valued at $2,328,000 after buying an additional 416 shares during the last quarter. Blair William & Co. IL raised its holdings in shares of Xylem by 0.5% in the first quarter. Blair William & Co. IL now owns 66,243 shares of the industrial products company’s stock valued at $5,648,000 after buying an additional 299 shares during the last quarter. Sei Investments Co. raised its holdings in shares of Xylem by 6.7% in the first quarter. Sei Investments Co. now owns 335,330 shares of the industrial products company’s stock valued at $28,590,000 after buying an additional 21,165 shares during the last quarter. Finally, Prudential PLC purchased a new stake in shares of Xylem in the first quarter valued at about $333,000. 87.96% of the stock is owned by hedge funds and other institutional investors.
Xylem Trading Down 0.5 %
Shares of XYL opened at $128.11 on Monday. The company has a current ratio of 1.76, a quick ratio of 1.30 and a debt-to-equity ratio of 0.22. The firm’s 50-day moving average is $126.36 and its two-hundred day moving average is $111.39. Xylem Inc. has a twelve month low of $87.59 and a twelve month high of $130.86. The firm has a market capitalization of $31.05 billion, a P/E ratio of 47.10, a PEG ratio of 2.55 and a beta of 1.10.
Xylem Increases Dividend
The firm also recently declared a quarterly dividend, which was paid on Wednesday, March 20th. Stockholders of record on Wednesday, February 21st were given a $0.36 dividend. The ex-dividend date was Tuesday, February 20th. This is a positive change from Xylem’s previous quarterly dividend of $0.33. This represents a $1.44 annualized dividend and a dividend yield of 1.12%. Xylem’s dividend payout ratio is currently 52.94%.
Analyst Upgrades and Downgrades
A number of equities research analysts have recently commented on the stock. Stifel Nicolaus upped their target price on shares of Xylem from $136.00 to $150.00 and gave the company a “buy” rating in a report on Wednesday, February 7th. BNP Paribas began coverage on shares of Xylem in a research note on Tuesday, March 12th. They set an “outperform” rating and a $150.00 price target on the stock. Royal Bank of Canada boosted their price target on shares of Xylem from $140.00 to $145.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 7th. Raymond James upgraded shares of Xylem from an “underperform” rating to a “market perform” rating in a research note on Thursday, January 4th. Finally, Robert W. Baird boosted their price target on shares of Xylem from $141.00 to $148.00 and gave the stock an “outperform” rating in a research note on Thursday, March 21st. Four analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $135.44.
Get Our Latest Report on Xylem
Insider Activity
In other news, CAO Geri-Michelle Mcshane sold 1,000 shares of the stock in a transaction that occurred on Tuesday, February 20th. The shares were sold at an average price of $122.89, for a total value of $122,890.00. Following the sale, the chief accounting officer now directly owns 2,935 shares in the company, valued at $360,682.15. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, CAO Geri-Michelle Mcshane sold 1,000 shares of the stock in a transaction that occurred on Tuesday, February 20th. The shares were sold at an average price of $122.89, for a total value of $122,890.00. Following the sale, the chief accounting officer now directly owns 2,935 shares in the company, valued at $360,682.15. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Franz Cerwinka sold 2,408 shares of the stock in a transaction that occurred on Thursday, February 8th. The shares were sold at an average price of $121.79, for a total transaction of $293,270.32. Following the completion of the sale, the senior vice president now owns 11,750 shares in the company, valued at $1,431,032.50. The disclosure for this sale can be found here. Company insiders own 0.90% of the company’s stock.
Xylem Profile
Xylem Inc, together with its subsidiaries, engages in the design, manufacture, and servicing of engineered products and solutions worldwide. It operates through four segments: Water Infrastructure, Applied Water, Measurement & Control Solutions, and Integrated Solutions and Services. The Water Infrastructure segment offers products, including water, storm water, and wastewater pumps; controls and systems; filtration, disinfection, and biological treatment equipment; and mobile dewatering equipment and rental services under the ADI, Flygt, Godwin, Sanitaire, Magneto, Neptune Benson, Ionpure, Leopold, Wedeco, and Xylem Vue brands.
Featured Articles
- Five stocks we like better than Xylem
- Why is the Ex-Dividend Date Significant to Investors?
- 5 Trends You Need to Know This Quarter
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- MarketBeat Week in Review – 4/8 – 4/12
- The How and Why of Investing in Biotech Stocks
- You Can Follow BlackRock’s Market View for Your Money
Receive News & Ratings for Xylem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xylem and related companies with MarketBeat.com's FREE daily email newsletter.